LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Biotechnology industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma. Register for these free reports at:
http://protraderdaily.com/register/
On Wednesday, August 16, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,082.21, 0.10% lower, with a total volume of 289,163,503 shares.
Additionally, the Healthcare index was down by 1.28%, ending the session at 62.27.
Pro-Trader Daily's complimentary research reports on the following stocks are now available: Concordia International Corporation (TSX: CXR), ProMetic Life Sciences Inc. (TSX: PLI), Theratechnologies Inc. (TSX: TH), and Cardiome Pharma Corporation (TSX: COM). Sign up now for your free membership and research reports at:
http://protraderdaily.com/register/
Concordia International Corp.
Oakville, Canada headquartered Concordia International Corp.'s stock declined 1.85%, to finish Wednesday's session at $1.59 with a total volume of 124,369 shares traded. Shares of the Company, which through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products, are trading below its 50-day and 200-day moving averages. Concordia International's 200-day moving average of $2.17 is above its 50-day moving average of $1.87. See our research report on CXR.TO at:
http://protraderdaily.com/optin/?symbol=CXR
ProMetic Life Sciences Inc.
On Wednesday, shares in Laval, Canada headquartered ProMetic Life Sciences Inc. recorded a trading volume of 2.74 million shares, which was higher than their three months average volume of 701,947 shares. The stock ended the day 8.76% lower at $1.25. Shares of the Company, which develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products, are trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $2.01 is above its 50-day moving average of $1.58. The complimentary research report on PLI.TO at:
http://protraderdaily.com/optin/?symbol=PLI
Theratechnologies Inc.
On Wednesday, shares in Montreal, Canada headquartered Theratechnologies Inc. ended the session 4.07% lower at $7.31 with a total volume of 91,754 shares traded. Theratechnologies' shares have surged 8.62% in the last three months and 185.55% in the previous one year. Shares of the Company, which addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients, are trading above its 200-day moving average. Furthermore, the stock's 50-day moving average of $7.85 is greater than its 200-day moving average of $6.35. Register for free and access the latest research report on TH.TO at:
http://protraderdaily.com/optin/?symbol=TH
Cardiome Pharma Corp.
Vancouver, Canada headquartered Cardiome Pharma Corp.'s stock closed the day flat at $4.95. The stock recorded a trading volume of 6,300 shares, which was above its three months average volume of 5,566 shares. Cardiome Pharma's shares have gained 5.54% in the past three months and 19.28% in the previous one year. Shares of the Company, which engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases, are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $5.56 is greater than its 200-day moving average of $4.75. Get free access to your research report on COM.TO at:
http://protraderdaily.com/optin/?symbol=COM
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily